<DOC>
	<DOCNO>NCT00655538</DOCNO>
	<brief_summary>This study ass safety , tolerability efficacy RO4607381 patient coronary heart disease ( CHD ) CHD risk equivalent . Patients randomize receive either RO4607381 600mg po daily placebo po daily . Endothelial function measure flow mediate dilatation blood pressure monitoring assess . The anticipated time study treatment 12 month , target sample size 500 individual .</brief_summary>
	<brief_title>A Study Assessing Effect RO4607381 Vascular Function Patients With Coronary Heart Disease ( CHD ) CHD-Risk Equivalent Patients</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Dalcetrapib</mesh_term>
	<criteria>adult patient , 1875 year age ; CHD CHD risk equivalent ; appropriately treat accepted LDLC level . treatment drug raise HDLC ( eg niacin , fibrates ) ; uncontrolled hypertension ; recent ( within 3 month ) clinically significant coronary event , transient ischemic attack cerebrovascular accident ; severe anemia ; poorly control diabetes .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>